TIDMODX

RNS Number : 4713N

Omega Diagnostics Group PLC

01 June 2022

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Result of Open Offer

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces the results of its Open Offer.

On 6 May 2022, Omega announced its intention to raise gross proceeds of up to GBP4.1 million by way of a Placing, Subscription and Open Offer (together the "Fundraising"), all at an issue price of 4 pence per New Ordinary Share.

The Open Offer closed for acceptances at 11:00 a.m. on 31 May 2022. The Company has received valid acceptances from Qualifying Shareholders in respect of their Basic Entitlements in respect of 1,560,453 New Ordinary Shares and has also received applications from Qualifying Shareholders under the Excess Application Facility in respect of 1,317,323 New Ordinary Shares. In aggregate this totals 2,877,776 New Ordinary Shares, representing approximately 5.77 per cent. of the Open Offer Shares. Accordingly, Qualifying Shareholders who have validly applied for Open Offer Shares will receive their full Basic Entitlements as well as those applied for under the Excess Application Facility.

Accordingly, a total of 5,002,776 New Ordinary Shares will be issued at the Issue Price (subject to the conditions noted below), of which, 2,125,000 New Ordinary Shares will be issued pursuant to the Subscription and 2,877,776 New Ordinary Shares will be issued pursuant to the Open Offer (the "Open Offer Shares"). This brings the gross proceeds of the Fundraising (including the Placing announced 6 May 2022) to GBP2.20 million before expenses.

General Meeting

The Open Offer and Subscription remain conditional on the approval by Shareholders of the Resolutions at the Company's General Meeting to be held on 6 June 2022 (or any adjournment thereof), the satisfaction of certain conditions in the Placing Agreement and Admission of the New Ordinary Shares to trading on AIM occurring at or before 8.00 a.m. on 8 June 2022 (or such later date as the Company and finnCap may agree, being not later than 8.00 a.m. on 22 June 2022).

The Company will announce the results of the General Meeting as soon as practicable after the meeting concludes.

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 13 May 2022.

Contacts:

 
 Omega Diagnostics Group PLC                                            www.omegadx.com 
 Jag Grewal, Chief Executive Officer                                    via Walbrook PR 
 Chris Lea, Chief Financial Officer 
 
 finnCap Ltd                                                         Tel: 020 7220 0500 
 Geoff Nash/Edward Whiley/George Dollemore (Corporate 
  Finance) 
 Alice Lane/ Harriet Ward (ECM) 
 
 Walbrook PR Limited                         Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                        Mob: 07980 541 893 
 Lianne Applegarth                                                   Mob: 07584 391 303 
 Sam Allen                                                           Mob: 07502 558 258

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROIUAVNRUKUVOAR

(END) Dow Jones Newswires

June 01, 2022 02:00 ET (06:00 GMT)

Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Omega Diagnostics.
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Omega Diagnostics.